Biosight Announces Initiation of Investigator Sponsored Phase II Clinical Trial of Aspacytarabine for Relapsed/Refractory AML and MDS with the Groupe Francophone Des Myélodysplasies

Biosight Ltd. announced the initiation of a Phase II trial to evaluate aspacytarabine, Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome or acute myeloid leukemia.